Skip to content

Advertisement

  • Poster presentation
  • Open Access

Effects of Multikinase inhibitors on pressure overload-induced right ventricular remodelling

  • 1,
  • 1,
  • 1, 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 3,
  • 3,
  • 3,
  • 3,
  • 3,
  • 3,
  • 1,
  • 1,
  • 1, 2,
  • 1 and
  • 1
Journal of Inflammation201310(Suppl 1):P37

https://doi.org/10.1186/1476-9255-10-S1-P37

Published: 14 August 2013

Keywords

  • Right Ventricular
  • Sorafenib
  • Sunitinib
  • Pressure Overload
  • Right Ventricular Function

Little is known about the effects of current PAH therapies and receptor tyrosine kinase inhibitors on heart remodelling. We sought to investigate the effects of the multikinase inhibitors sunitinib (PDGFR-, VEGFR- and KIT-inhibitor) and sorafenib (raf1/b-, VEGFR-, PDGFR-inhibitor) on pressure overload induced right ventricular (RV) remodelling. We investigated the effects of the kinase inhibitors on hemodynamics and remodelling in rats subjected either to monocrotaline (MCT)-induced PH or to surgical pulmonary artery banding (PAB). MCT rats were treated from day 21 to 35 with either vehicle, sunitinib (1 mg/kg, 5 mg/kg and 10 mg/kg/day) or sorafenib (10 mg/kg/day). PAB rats were treated with vehicle, sunitinib (10 mg/kg/day) or sorafenib (10mg/kg/day) from day 7 to 21. RV function and remodelling were determined using echocardiography, invasive hemodynamic measurement and histomorphometry. Treatment with both sorafenib and sunitinib decreased right ventricular systolic pressure, pulmonary vascular remodelling, RV hypertrophy and fibrosis in MCT rats. This was associated with an improvement of RV function. Importantly, after PAB, both compounds reversed RV chamber and cellular hypertrophy, reduced RV interstitial and perivascular fibrosis, and improved RV function. We demonstrated that sunitinib and sorafenib reversed RV remodelling and significantly improved RV function measured via a range of invasive and non-invasive cardiopulmonary endpoints in experimental models of RV hypertrophy.

Authors’ Affiliations

(1)
Universities of Giessen and Marburg Lung Centre (UGMLC), Giessen, Germany
(2)
Department of Lung Development and Remodelling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
(3)
Inflammation and Remodeling Research, Pfizer Cambridge, Massachusetts, USA

Copyright

© Kojonazarov et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement